The collaboration’s objective is to enable the early prediction of clinical efficacy of Alligator´s pipeline candidates through the analysis of potential systemic biomarkers. In the longer-term, this may benefit patients through appropriate treatment selection based on biomarker analysis. Biomarker selection is critical to the success of this strategy, and Stanford´s expertise, including RNA sequencing and proteomic analysis, will be instrumental in this.
Alligator has worked with Stanford since 2014, drawing on its pioneering work in immuno-oncology. The principal investigator at Stanford, Prof Dean Felsher, is an expert in the field of oncogene-induced cancer immune evasion and the relationship between oncogenes and cancer immunotherapy. The next step in the biomarker program will be to evaluate Alligator´s compounds in Stanford´s pre-clinical models.
“The expanded collaboration with Stanford University will accelerate the pre-clinical development of our pipeline projects and strengthen the biomarker discovery program by drawing on their world-leading expertise in this area”, says Per Norlén, CEO of Alligator Bioscience. “Tumor-directed immunotherapy has the potential to add efficacy without adding dose-limiting toxicity, and the biomarker strategy will be essential to fully deliver on this.”
For further information, please contact:
Per Norlén, CEO
Rein Piir, VP Investor Relations
Telephone: +46 708 537292
Per-Olof Schrewelius, CFO
Telephone: +46 46 286 42 85
The information in the press release was submitted for publication on 7 August 2017 at 08:30 (CET).
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical product candidates (ADC-1013, ATOR-1015, ATOR-1017, and ALG.APV-527) and novel research candidates. ADC-1013 is licensed to Janssen Biotech, Inc., part of J&J, for development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit https://www.alligatorbioscience.se